Compare SATL & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SATL | AUTL |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.2M | 596.2M |
| IPO Year | 2021 | 2025 |
| Metric | SATL | AUTL |
|---|---|---|
| Price | $3.98 | $1.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $10.20 | $8.73 |
| AVG Volume (30 Days) | ★ 4.4M | 1.5M |
| Earning Date | 11-09-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,707,000.00 | $10,120,000.00 |
| Revenue This Year | $166.10 | $98.68 |
| Revenue Next Year | $32.37 | $28.47 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 37.58 | ★ 496.00 |
| 52 Week Low | $1.26 | $1.18 |
| 52 Week High | $12.00 | $2.58 |
| Indicator | SATL | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 34.52 | 33.76 |
| Support Level | $3.34 | $1.55 |
| Resistance Level | $6.18 | $1.73 |
| Average True Range (ATR) | 0.32 | 0.09 |
| MACD | -0.19 | -0.02 |
| Stochastic Oscillator | 7.34 | 7.78 |
Satellogic Inc is a vertically integrated Earth observation company that designs, manufactures, and operates satellite systems, delivering decision-grade insights at scale to government and commercial customers. Through an end-to-end production and operations model, it provides governments with flexible options across their journey toward sovereign Earth observation. From access to high-frequency imagery and managed space systems to full satellite ownership, to supporting autonomous data availability and long-term technological independence. It has monitoring and alert-driven workflows that help defense and intelligence agencies, civil governments, and commercial operators transition from reactive tasking to proactive decision-making, providing mission-critical data when needed.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.